Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 5.60% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTREGENERON PHARMACEUTICALS, INC.'s latest supported as-filed period reports revenue of $4.3B, 16.7% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 5.60% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 18.95% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 16.73% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 71.88% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value 30.15% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 38.03% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 16.7%; Operating margin moved 78 bp higher; Operating income increased 19.8%.
3 evidence-backed componentsOperating margin changed +78 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
REGN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001663758-26-000002SEC ↗4Sep 3, 2026Period Sep 2, 20260001992352-26-000007SEC ↗4Aug 21, 2026Period Aug 19, 20260001238303-26-000002SEC ↗4Aug 20, 2026Period Aug 18, 20260001697422-26-000002SEC ↗4Aug 12, 2026Period Aug 10, 20260001992352-26-000005SEC ↗4Aug 12, 2026Period Aug 10, 20260001681643-26-000006SEC ↗13F-HRAug 7, 2026Period Jun 30, 20260001104659-26-092709SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 2, 2026Filed Sep 3, 2026 | Guarini KathrynDirector | Option ExerciseDirect | 400 | $719 | $287,748 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Guarini KathrynDirector | Open Market SaleDirect | 400 | $850 | $340,000 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Guarini KathrynDirector | Option ExerciseDirect | 400 | $0 | $0 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | LAROSA JOSEPH JEVP General Counsel and Secret | Option ExerciseDirect | 12,282 | $382 | $4.7M | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 5.66% · OPTIONAL
Revenue changed +16.7% from the comparable as-filed period.
Operating income changed +19.8% from the comparable as-filed period.
Inventory / revenue changed -1533 basis points from the comparable as-filed period.
Cash & equivalents changed +23.0% from the comparable as-filed period.
Research & development changed +14.8% from the comparable as-filed period.
Net income changed -6.8% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000872589-26-000025| Tax WithholdingDirect |
| 9,019 |
| $830 |
| $7.5M |
| Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | LAROSA JOSEPH JEVP General Counsel and Secret | Option ExerciseDirect | 12,282 | $0 | $0 | Form 4 ↗ |